CLIC-INNOVATION
27.8.2024 13:08:28 CEST | Business Wire | Press release
Rare earth elements and rare magnets play a crucial role in advancing the green energy transition and achieving the goals of the European Green Deal. While the EU currently relies heavily on imports from a few countries— with approximately 90% of REEs* coming from outside the EU—this presents an opportunity to develop European expertise and forge strategic partnerships in rare earth metals processing. Strengthening these capabilities within Europe is key to reaching our ambitious targets. Additionally, while challenges remain in REEs recycling, with current rates being less than 5% and some extraction processes needing sustainability improvements, these challenges also present a significant potential for innovation and growth. As demand for REEs increases, driven by their use in electric vehicles, wind turbine motors, and electrolysers for clean hydrogen, there is a tremendous opportunity to enhance recycling efforts and establish more sustainable extraction processes within the EU.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240827785891/en/
CLIC Innovation: REMHub Project Develops a Digital Innovation Hub for Rare Earth Elements and Rare Magnets (Copyright (c) 2024 Phawat/Shutterstock)
Project targets and development areas
REMHub will develop, test and pilot novel technologies for the exploration and primary production of rare earth elements and for recovering them from side streams to enhance supply security of REEs and rare magnets in the EU. In addition, the project will develop Re-X (Recycle, Reuse, refurbishment and repurposing) technologies for rare earths and valuable metals from end-of-life products as well as electric machine design for easier permanent magnet recycling. The project will also identify and engage relevant stakeholders to develop REE value chains in the EU. The innovation hub will ensure that the novel technologies developed in the project will be commercialized and offered as services via digital platform in the future.
The project’s multi-stakeholder communication and dissemination efforts are designed to actively involve and engage the public and various stakeholders, fostering trust and raising awareness about the importance of REEs. These activities also aim to build essential capacities within the EU. The hub focuses on transformative material sourcing for REEs and REE magnets, including innovations in traceability, digital twinning, and digital passports. Our project partners span the entire REE value chain, from mineral exploration and processing to metal production, magnet manufacturing, and recycling.
The project is committed to a safe and sustainable by design (SSbD) framework, embracing a Re-X approach that prioritizes recycling, reuse, refurbishment, and repurposing, while integrating features for easy dismantling and circularity. REMHub is set to significantly enhance the security of REE supply in the EU. With the support of our digital innovation hub, it will accelerate the development of technologies and services, enabling faster and easier market entry. By the conclusion of the project, future organizations will find it much easier to access sustainably developed REE expert services within the EU.
Project in a nutshell
The project will commence at the beginning of October and last for four years. The project consortium consists of 24 partners from six countries: Finland, Estonia, Spain, Ireland, Slovenia, and Italy. The project preparation and consortium coordination were led by the Finnish organization CLIC Innovation, which also serves as the project coordinator. The estimated total volume of the project is 18 million euros, of which 16 million euros is EU funding. The EU Horizon "resilient value chains" funding instrument supports European sustainable development value chain projects with financing from the European Commission.
* source: https://scrreen.eu/wp-content/uploads/2023/08/SCRREEN2_factsheets_REE-EUROSTAT.pdf
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827785891/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
